Experienced in Astrocytoma

Dr. Alison K. Conlin

Oncology

Providence

4805 Northeast Glisan Street, Suite 11N-1,

Portland, OR

Clinical Trials:Currently Recruiting for 2 Trials

Accepting New Patients

Offers Telehealth

Experienced in Astrocytoma

Providence

4805 Northeast Glisan Street, Suite 11N-1,

Portland, OR

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Alison Conlin is an Oncologist in Portland, Oregon. Dr. Conlin is rated as an Experienced provider by MediFind in the treatment of Astrocytoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Endoscopy, and Tissue Biopsy. Dr. Conlin is currently accepting new patients.

Her clinical research consists of co-authoring 38 peer reviewed articles and participating in 136 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 6 clinical trials in the study of Astrocytoma.

Specialties

Oncology

Licenses

Internal Medicine in NY

Hospital Affiliations

Ohsu Hospital And Clinics

Providence Milwaukie Hospital

Providence Portland Medical Center

Providence St Vincent Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem BCBS

Blue Cross Blue Shield

Blue Shield of California

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE-MEDICAID PLAN
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

BridgeSpan

Cambia Health Solutions

EPO
INSURANCE PLAN
MEDICARE MAPD
MEDICARE PDP
OTHER COMMERCIAL
OTHER MEDICARE
PPO

Cigna

Group Health Cooperative

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark

HMSA

Humana

HMO
INDEMNITY
POS
PPO

Kaiser Permanente

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
OTHER MEDICARE
POS
PPO

Managed Medicaid

OTHER MANAGED MEDICAID

Medicaid

OTHER MEDICAID
STATE MEDICAID

Medicare

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE PART D

Moda Health

PacificSource

Premera Blue Cross

INSURANCE PLAN
MEDICARE MAPD
OTHER COMMERCIAL
PPO

Prominence Health

Regence

SelectHealth

UnitedHealthcare

Walgreens

MEDICARE DISCOUNT CARD
MEDICARE PDP
OTHER MEDICARE

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 21 Less Insurance Carriers -

Locations

4805 Northeast Glisan Street, Suite 11N-1, Portland, OR 97213

Call: 503-215-5696

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

133 Clinical Trials

Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR

Enrollment Status: Recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug

Study Phase: Phase 2

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing

Enrollment Status: Recruiting

Publish Date: January 26, 2026

Intervention Type: Drug, Other, Radiation

Study Drug: Cisplatin

Study Phase: Phase 2

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Biological, Radiation, Other

Study Drugs: Cisplatin, Nivolumab

Study Phase: Phase 3

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Biological, Procedure

Study Drug: Pembrolizumab

Study Phase: Phase 3

Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Biological, Procedure

Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate

Study Phase: Phase 2/Phase 3

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer

Enrollment Status: Suspended

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Biological, Radiation

Study Drugs: Carboplatin, Ipilimumab, Nab-paclitaxel, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed

Study Phase: Phase 2/Phase 3

A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

Enrollment Status: Suspended

Publish Date: February 12, 2026

Intervention Type: Biological, Drug, Procedure, Radiation

Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel

Study Phase: Phase 2/Phase 3

A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Biological, Drug

Study Drugs: Carboplatin, Nivolumab, Paclitaxel

Study Phase: Phase 3

A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Drug

Study Drug: Erlotinib Hydrochloride

Study Phase: Phase 3

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Drug, Biological

Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax

Study Phase: Phase 3

Molecular Analysis for Therapy Choice (MATCH)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib

Study Phase: Phase 2

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Drug

Study Drugs: Olaparib, Temozolomide

Study Phase: Phase 2

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Biological

Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium

Study Phase: Phase 3

A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Biological

Study Drugs: Atezolizumab, Bevacizumab, Carboplatin, Cetuximab, Cisplatin, Docetaxel

Study Phase: Phase 2/Phase 3

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Biological

Study Drugs: Gemcitabine Hydrochloride, Pembrolizumab

Study Phase: Phase 2

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Biological, Drug

Study Phase: Not Applicable

Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women

Enrollment Status: Active_not_recruiting

Publish Date: February 11, 2026

Intervention Type: Other, Drug

Study Drugs: Docetaxel, Paclitaxel

Study Phase: Phase 2

A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers

Enrollment Status: Active_not_recruiting

Publish Date: February 11, 2026

Intervention Type: Drug

Study Drug: Enzalutamide

Study Phase: Phase 2

Longitudinal Assessment of Financial Burden in Patients With Colon or Rectal Cancer Treated With Curative Intent

Enrollment Status: Active_not_recruiting

Publish Date: February 11, 2026

Intervention Type: Other

A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: February 11, 2026

Intervention Type: Drug

Study Drugs: Capecitabine, Carboplatin, Cisplatin

Study Phase: Phase 3

A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 10, 2026

Intervention Type: Drug, Procedure, Other

Study Drugs: Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil

Study Phase: Phase 3

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

Enrollment Status: Suspended

Publish Date: February 05, 2026

Intervention Type: Biological, Drug, Procedure, Other

Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab

Study Phase: Phase 3

Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)

Enrollment Status: Active_not_recruiting

Publish Date: February 05, 2026

Intervention Type: Drug

Study Drugs: Avelumab, Cetuximab

Study Phase: Phase 2

A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas

Enrollment Status: Suspended

Publish Date: February 05, 2026

Intervention Type: Drug

Study Drugs: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral Azacitidine

Study Phase: Phase 2

CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 05, 2026

Intervention Type: Other, Drug

Study Drugs: Enzalutamide, Rucaparib Camsylate, Leuprolide Acetate, Goserelin Acetate, Degarelix

Study Phase: Phase 3

Genomically-Guided Treatment Trial in Brain Metastases

Enrollment Status: Suspended

Publish Date: February 04, 2026

Intervention Type: Drug

Study Drugs: Abemaciclib, Paxalisib, Entrectinib

Study Phase: Phase 2

A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease

Enrollment Status: Suspended

Publish Date: February 03, 2026

Intervention Type: Biological

Study Drugs: Blinatumomab, Inotuzumab

Study Phase: Phase 2

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Enrollment Status: Active_not_recruiting

Publish Date: February 02, 2026

Intervention Type: Other, Procedure, Drug

Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin

Study Phase: Phase 3

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

Enrollment Status: Active_not_recruiting

Publish Date: February 02, 2026

Intervention Type: Drug, Biological, Other

Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax

Study Phase: Phase 3

A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: January 30, 2026

Intervention Type: Drug, Procedure

Study Drugs: Carmustine, Cytarabine, Etoposide, Thiotepa, Granulocyte Colony-Stimulating Factor

Study Phase: Phase 2

A Phase I/II Study of MK-3475 With Gemcitabine in Patients With Previously-Treated Advanced Non-small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: January 29, 2026

Intervention Type: Drug

Study Drugs: MK-3475, Gemcitabine

Study Phase: Phase 1/Phase 2

A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)

Enrollment Status: Active_not_recruiting

Publish Date: January 28, 2026

Intervention Type: Drug, Radiation

Study Drugs: Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin

Study Phase: Phase 3

A Phase 1b Study of Abemaciclib in Combination With Therapies for Patients With Metastatic Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Drug

Study Drugs: LY2835219, Letrozole, Anastrozole, Tamoxifen, Exemestane, Everolimus, Trastuzumab, LY3023414, Fulvestrant, Pertuzumab, Loperamide, Endocrine therapy

Study Phase: Phase 1

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Drug

Study Drugs: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine

Study Phase: Phase 2/Phase 3

A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Procedure, Drug, Radiation

Study Drugs: Capecitabine, Fluorouracil, Mitomycin

Study Phase: Phase 2

(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Procedure, Biological, Drug, Radiation

Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine

Study Phase: Phase 2

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Biological, Drug

Study Drugs: Acalabrutinib, Bendamustine, Bendamustine Hydrochloride, Cytarabine, Rituximab

Study Phase: Phase 2

ARM: Axillary Reverse Mapping - A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence After Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection With and Without Axillary Reverse Mapping

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Drug, Procedure

Study Drug: Isosulfan Blue

Study Phase: Phase 3

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Procedure

Study Phase: Phase 3

Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS for Resected Metastatic Brain Disease

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Radiation, Procedure, Other

Study Phase: Phase 3

A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Biological, Procedure

Study Drug: Rituximab

Study Phase: Phase 3

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Procedure

Study Phase: Not Applicable

A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer

Enrollment Status: Completed

Publish Date: January 22, 2026

Intervention Type: Procedure

Study Phase: Phase 3

Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

Enrollment Status: Active_not_recruiting

Publish Date: January 22, 2026

Intervention Type: Drug, Radiation

Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine

Study Phase: Phase 3

Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study

Enrollment Status: Active_not_recruiting

Publish Date: January 22, 2026

Intervention Type: Drug

Study Drugs: Fulvestrant, Anastrozole

Study Phase: Phase 3

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: January 21, 2026

Intervention Type: Drug, Procedure

Study Drugs: Cytarabine, Daunorubicin, Uproleselan

Study Phase: Phase 2/Phase 3

Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

Enrollment Status: Active_not_recruiting

Publish Date: December 22, 2025

Intervention Type: Other, Dietary supplement, Drug

Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan

Study Phase: Phase 3

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Enrollment Status: Active_not_recruiting

Publish Date: December 19, 2025

Intervention Type: Other, Drug

Study Drug: Crizotinib

Study Phase: Phase 3

View 48 Less Clinical Trials

38 Total Publications

Association of Genetic Predisposition to Inflammation With Cancer-Related Cognitive Impairment and Fatigue in Women Who Received Chemotherapy for Nonmetastatic Breast Cancer.

Journal: JCO precision oncology

Published: September 16, 2025

View All 38 Publications

Similar Doctors

Advanced in Astrocytoma

Dr. Robert C. Lufkin

Oncology

Advanced in Astrocytoma

Dr. Robert C. Lufkin

Oncology

Northwest Cancer Specialists PC

265 N Broadway,

Portland, OR

(5.2 miles away)

503-280-1223

Languages Spoken:

English, Castilian, Spanish

See accepted insurances

Accepting New Patients

Offers Telehealth

Robert Lufkin is an Oncologist in Portland, Oregon. Dr. Lufkin is rated as a Distinguished provider by MediFind in the treatment of Astrocytoma. His top areas of expertise are Glioblastoma, Embryonal Tumor with Multilayered Rosettes, Ependymoma, and Pediatric Low-Grade Glioma (pLGG). Dr. Lufkin is currently accepting new patients.

Experienced in Astrocytoma

Dr. Ted L. Huang

Hematology Oncology | Hematology | Oncology

Experienced in Astrocytoma

Dr. Ted L. Huang

Hematology Oncology | Hematology | Oncology

University Professional Services

3181 Sw Sam Jackson Park Rd,

Portland, OR

(4.2 miles away)

503-494-8311

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Ted Huang is a Hematologist Oncology specialist and a Hematologist in Portland, Oregon. Dr. Huang is rated as an Advanced provider by MediFind in the treatment of Astrocytoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Large-Cell Lung Carcinoma, and Non-Small Cell Lung Cancer (NSCLC). Dr. Huang is currently accepting new patients.

Experienced in Astrocytoma

Dr. Matthew D. Tipping

Hematology Oncology | Hematology | Oncology

Experienced in Astrocytoma

Dr. Matthew D. Tipping

Hematology Oncology | Hematology | Oncology

Interstate Medical Office Central

3600 N Interstate Ave,

Portland, OR

(5.1 miles away)

800-813-2000

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Matthew Tipping is a Hematologist Oncology specialist and a Hematologist in Portland, Oregon. Dr. Tipping is rated as an Experienced provider by MediFind in the treatment of Astrocytoma. His top areas of expertise are Astrocytoma, Glioblastoma, Brain Tumor, and Glioma. Dr. Tipping is currently accepting new patients.

VIEW MORE ASTROCYTOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Conlin's expertise for a condition

ConditionClose